The present invention relates to macrocyclic diamine derivatives of formula II, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the macrocyclic diamine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

The present invention relates to macrocyclic diamine derivatives of formula II, including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the macrocyclic diamine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

A series of new macrocycles and cage-like molecules are obtained in a high yield from a bis-(2,4-dialkoxyphenyl)arene (naphthalene, anthracene, pyrene, porphyrin, etc.) or a tris-(2,4-dialkoxyphenyl)arene (benzene, sym-tribenzobenzene) and paraformaldehyde under the catalysis of a Lewis acid. In addition, perhydroxybiphenylarenes (tetrabiphenyl trimer, naphthalene dimer, etc.) can be obtained by means of demethylation, and a variety of water-soluble derivatives can be obtained by further modification, with same exhibiting a good bond ability for guest molecules (purpurine, etc.). Moreover, the functional group introduced into the backbone enables the macrocycle to have excellent adsorption and separation capabilities and a photophysical property. The macrocyclic and cage-like molecules have commercially available raw materials, are simple to synthesize, have a high yield, and are convenient to modify, such that same have wide application prospects in gas adsorption and separation, facilitate performance improvement of luminescent materials, perform adsorption of water-soluble toxic substances, etc.

A series of new macrocycles and cage-like molecules are obtained in a high yield from a bis-(2,4-dialkoxyphenyl)arene (naphthalene, anthracene, pyrene, porphyrin, etc.) or a tris-(2,4-dialkoxyphenyl)arene (benzene, sym-tribenzobenzene) and paraformaldehyde under the catalysis of a Lewis acid. In addition, perhydroxybiphenylarenes (tetrabiphenyl trimer, naphthalene dimer, etc.) can be obtained by means of demethylation, and a variety of water-soluble derivatives can be obtained by further modification, with same exhibiting a good bond ability for guest molecules (purpurine, etc.). Moreover, the functional group introduced into the backbone enables the macrocycle to have excellent adsorption and separation capabilities and a photophysical property. The macrocyclic and cage-like molecules have commercially available raw materials, are simple to synthesize, have a high yield, and are convenient to modify, such that same have wide application prospects in gas adsorption and separation, facilitate performance improvement of luminescent materials, perform adsorption of water-soluble toxic substances, etc.

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Provided herein are caspofungin derivatives having anti-fungal activity and methods of using same for treating fungal infection. Further provided are methods and kits for determining responsiveness to an anti-fungal activity of an echinocandin compound.

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Compounds of Formula I: ##STR00001##
wherein: one of X and X′ is N and the other of X and X′ is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.